301520 万邦医药
已收盘 08-21 15:00:00
资讯
新帖
简况
万邦医药：截止8月8日股东人数为9,277户
证券之星 · 03:36
万邦医药：截止8月8日股东人数为9,277户
万邦医药：坚持通过稳健经营和技术创新提升核心竞争力
金融界 · 08-18
万邦医药：坚持通过稳健经营和技术创新提升核心竞争力
万邦医药(301520)7月31日股东户数1万户，较上期增加0.33%
证券之星 · 08-11
万邦医药(301520)7月31日股东户数1万户，较上期增加0.33%
万邦医药(301520)7月31日股东户数1万户，较上期增加0.33%
证券之星 · 08-06
万邦医药(301520)7月31日股东户数1万户，较上期增加0.33%
CRO概念盘中跳水，万邦医药跌1.49%
市场透视 · 08-04
CRO概念盘中跳水，万邦医药跌1.49%
万邦医药：公司为创新药企业提供临床试验外包服务
证券之星 · 07-29
万邦医药：公司为创新药企业提供临床试验外包服务
万邦医药：截止2025年7月18日股东人数为9,918户
证券之星 · 07-22
万邦医药：截止2025年7月18日股东人数为9,918户
万邦医药股价下跌1.95% 公司澄清与辉瑞、阿斯利康无合作关系
金融界 · 07-15
万邦医药股价下跌1.95% 公司澄清与辉瑞、阿斯利康无合作关系
万邦医药：截止2025年6月10日，公司的股东人数为12,206户
证券之星 · 06-17
万邦医药：截止2025年6月10日，公司的股东人数为12,206户
【CRO概念震荡走低 联化科技跌停】CRO概念震荡走低，联化科技跌停，万邦医药、河化股份、翰宇药业、睿智医药、昭衍新药等跟跌。
金融界 · 06-11
【CRO概念震荡走低 联化科技跌停】CRO概念震荡走低，联化科技跌停，万邦医药、河化股份、翰宇药业、睿智医药、昭衍新药等跟跌。
万邦医药收盘上涨8.99%，滚动市盈率44.32倍，总市值30.00亿元
金融界 · 06-09
万邦医药收盘上涨8.99%，滚动市盈率44.32倍，总市值30.00亿元
万邦医药：公司有为改善干眼症的麦角硫因洗眼液项目提供临床功效试验服务
证券之星 · 05-16
万邦医药：公司有为改善干眼症的麦角硫因洗眼液项目提供临床功效试验服务
【万邦医药：与仅三生物在麦角硫因方面有临床项目合作】万邦医药在互动平台表示，公司与仅三生物在麦角硫因方面有临床项目合作，公司为仅三生物研发的产品提供功效性验证临床服务。
金融界 · 05-16
【万邦医药：与仅三生物在麦角硫因方面有临床项目合作】万邦医药在互动平台表示，公司与仅三生物在麦角硫因方面有临床项目合作，公司为仅三生物研发的产品提供功效性验证临床服务。
万邦医药：公司研究了麦角硫因的潜在多种功效
证券之星 · 05-16
万邦医药：公司研究了麦角硫因的潜在多种功效
万邦医药：公司与仅三生物在麦角硫因方面有临床项目合作
证券之星 · 05-16
万邦医药：公司与仅三生物在麦角硫因方面有临床项目合作
万邦医药收盘下跌2.27%，滚动市盈率35.14倍，总市值23.79亿元
金融界 · 04-28
万邦医药收盘下跌2.27%，滚动市盈率35.14倍，总市值23.79亿元
万邦医药(301520.SZ)发布2024年度业绩，归母净利润8553.07万元，下降20.87%
智通财经网 · 04-21
万邦医药(301520.SZ)发布2024年度业绩，归母净利润8553.07万元，下降20.87%
万邦医药(301520.SZ)发布一季度业绩，归母净利润1184.93万元，下降60.09%
智通财经 · 04-21
万邦医药(301520.SZ)发布一季度业绩，归母净利润1184.93万元，下降60.09%
万邦医药最新公告：证券事务代表杨婷因个人原因辞职
证券之星 · 02-28
万邦医药最新公告：证券事务代表杨婷因个人原因辞职
加载更多
公司概况
公司名称：
安徽万邦医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2023-09-25
主营业务：
安徽万邦医药科技股份有限公司的主营业务是为医药企业和其他医药研发机构提供专业化医药研发外包服务。公司的主要产品是临床试验现场管理（SMO）、生物样本分析（BA）、数据管理与统计分析（DM/ST）、处方工艺研究、质量研究、稳定性研究。
发行价格：
67.88
{"stockData":{"symbol":"301520","market":"SZ","secType":"STK","nameCN":"万邦医药","latestPrice":45.83,"timestamp":1755759822000,"preClose":46.09,"halted":0,"volume":984600,"delay":0,"changeRate":-0.0056,"floatShares":22423000,"shares":66666700,"eps":1.0154,"marketStatus":"已收盘","change":-0.26,"latestTime":"08-21 15:00:00","open":45.95,"high":46.39,"low":45.65,"amount":45249200,"amplitude":0.0161,"askPrice":45.85,"askSize":15,"bidPrice":45.83,"bidSize":21,"shortable":0,"etf":0,"ttmEps":1.0154,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1755826200000},"marketStatusCode":5,"adr":0,"adjPreClose":46.09,"symbolType":"stock","openAndCloseTimeList":[[1755739800000,1755747000000],[1755752400000,1755759600000]],"highLimit":50.7,"lowLimit":41.48,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":66666667,"isCdr":false,"pbRate":2.05,"roa":"--","peRate":45.134922,"roe":"0.78%","epsLYR":1.28,"committee":0.155556,"marketValue":3055000000,"turnoverRate":0.0439,"status":1,"floatMarketCap":1028000000},"requestUrl":"/m/hq/s/301520","defaultTab":"news","newsList":[{"id":"2561376764","title":"万邦医药：截止8月8日股东人数为9,277户","url":"https://stock-news.laohu8.com/highlight/detail?id=2561376764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561376764?lang=zh_cn&edition=full","pubTime":"2025-08-21 11:36","pubTimestamp":1755747387,"startTime":"0","endTime":"0","summary":"证券之星消息，万邦医药(301520)08月20日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止8月8日股东人数是多少？谢谢万邦医药回复：尊敬的投资者您好，截止2025年8月8日，公司的股东人数为9,277户。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100014494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2560705449","title":"万邦医药：坚持通过稳健经营和技术创新提升核心竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2560705449","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560705449?lang=zh_cn&edition=full","pubTime":"2025-08-18 16:40","pubTimestamp":1755506447,"startTime":"0","endTime":"0","summary":"金融界8月18日消息，有投资者在互动平台向万邦医药提问：2025年中报即将公布，中期分红回报投资者吗？公司回答表示：尊敬的投资者您好，公司始终高度重视股东回报，坚持通过稳健经营、精细化管理和持续的技术创新，不断提升核心竞争力与盈利能力，致力于为股东创造长期稳定的价值。如有相关计划，公司将严格按照规定及时履行信息披露义务。感谢您的关注！","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/18164052505203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301520","BK0216"],"gpt_icon":0},{"id":"2558657653","title":"万邦医药(301520)7月31日股东户数1万户，较上期增加0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558657653","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558657653?lang=zh_cn&edition=full","pubTime":"2025-08-11 17:18","pubTimestamp":1754903937,"startTime":"0","endTime":"0","summary":"证券之星消息，近日万邦医药披露，截至2025年7月31日公司股东户数为9951.0户，较7月18日增加33.0户，增幅为0.33%。在医疗服务行业个股中，万邦医药股东户数低于行业平均水平，截至7月31日，医疗服务行业平均股东户数为4.53万户。从股价来看，2025年7月18日至2025年7月31日，万邦医药区间涨幅为5.86%，在此期间股东户数增加33.0户，增幅为0.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081100028092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2557324137","title":"万邦医药(301520)7月31日股东户数1万户，较上期增加0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557324137","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557324137?lang=zh_cn&edition=full","pubTime":"2025-08-06 17:13","pubTimestamp":1754471635,"startTime":"0","endTime":"0","summary":"证券之星消息，近日万邦医药披露，截至2025年7月31日公司股东户数为9951.0户，较7月18日增加33.0户，增幅为0.33%。在医疗服务行业个股中，万邦医药股东户数低于行业平均水平，截至7月31日，医疗服务行业平均股东户数为4.45万户。从股价来看，2025年7月18日至2025年7月31日，万邦医药区间涨幅为5.86%，在此期间股东户数增加33.0户，增幅为0.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080600027847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2556799178","title":"CRO概念盘中跳水，万邦医药跌1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556799178","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556799178?lang=zh_cn&edition=full","pubTime":"2025-08-04 09:36","pubTimestamp":1754271385,"startTime":"0","endTime":"0","summary":"08月04日，CRO概念盘中跳水，截至09点36分，CRO概念整体指数下跌2.04%，报579.060点。从个股上来看，该概念的成分股中，万邦医药跌1.49%，宣泰医药、百诚医药、蔚蓝生物跌幅居前。从资金上来看，截止发稿，CRO概念主力净流入为-2.25亿，其中阳光诺和受到资金热捧，主力净流入3747.26万；拉长时间线来看，该板块近20日主力资金净流入-46.16亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080409362597318e51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080409362597318e51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["301520","BK0226","603739","BK0216"],"gpt_icon":0},{"id":"2555089590","title":"万邦医药：公司为创新药企业提供临床试验外包服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2555089590","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555089590?lang=zh_cn&edition=full","pubTime":"2025-07-29 11:33","pubTimestamp":1753759992,"startTime":"0","endTime":"0","summary":"投资者提问：从国家药监局获悉：今年上半年我国批准创新药43个、创新医疗器械45个，同比分别增长59%和87%，改革政策红利正在转化为产业发展动力。去年以来，国家药监局在11个省级局开展优化药品补充申请改革试点，需要核查检验的补充申请审评时限由200个工作日缩短为60个工作日，同时，探索在30个工作日内完成重点创新药临床试验审评审批。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900016323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301520","BK1583","06978","03347","159992","BK1574","BK1141","BK1161","BK1576","BK0216"],"gpt_icon":0},{"id":"2553400864","title":"万邦医药：截止2025年7月18日股东人数为9,918户","url":"https://stock-news.laohu8.com/highlight/detail?id=2553400864","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553400864?lang=zh_cn&edition=full","pubTime":"2025-07-22 08:54","pubTimestamp":1753145655,"startTime":"0","endTime":"0","summary":"证券之星消息，万邦医药(301520)07月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司最新一期的股东人数是多少？谢谢万邦医药回复：尊敬的投资者您好，截止2025年7月18日，公司的股东人数为9,918户。感谢您的关注，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072200007362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2551917381","title":"万邦医药股价下跌1.95% 公司澄清与辉瑞、阿斯利康无合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2551917381","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551917381?lang=zh_cn&edition=full","pubTime":"2025-07-16 02:30","pubTimestamp":1752604208,"startTime":"0","endTime":"0","summary":"万邦医药股价报45.31元，较前一交易日下跌0.90元。当日开盘价为45.71元，最高触及45.90元，最低下探44.35元，成交量为23988手，成交金额达1.08亿元。万邦医药属于医疗服务板块，公司专注于医药研发领域。公开资料显示，该公司总市值为30.21亿元，流通市值为10.16亿元。公司方面消息显示，万邦医药在投资者互动平台明确表示，目前与辉瑞、阿斯利康等国际制药巨头均无合作关系。该表态是针对投资者关于公司业务合作情况的询问作出的回应。资金流向数据显示，万邦医药当日主力资金净流出964.66万元。风险提示：股市有风险，投资需谨慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/16023051721498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE000M9KFDE8.USD","LU1894683264.USD","BK4533","IE00BBT3K403.USD","LU2417539215.USD","LU0225771236.USD","SG9999002224.SGD","BK0216","LU0320765992.SGD","LU0889565916.HKD","LU1066053197.SGD","IE00BLSP4452.SGD","BK4592","LU1057294990.SGD","SG9999011175.SGD","SG9999013999.USD","LU1883839398.USD","SG9999001176.USD","LU0170899867.USD","BK4568","LU1829250122.USD","LU0321505439.SGD","LU1023059063.AUD","LU2462157665.USD","LU1066051498.USD","LU0109394709.USD","IE00BLSP4239.USD","LU0306806265.USD","SGXZ57979304.SGD","LU0122379950.USD","BK4599","SG9999001176.SGD","AZN","BK4588","IE00B19Z3581.USD","BK4007","BK4534","LU0985481810.HKD","IE0002270589.USD","SG9999002232.USD","LU0456855351.SGD","301520","LU0225284248.USD","BK4585","LU0289739699.SGD","LU2456880835.USD","LU2236285917.USD","LU1894683348.USD","LU0234572021.USD"],"gpt_icon":0},{"id":"2544825579","title":"万邦医药：截止2025年6月10日，公司的股东人数为12,206户","url":"https://stock-news.laohu8.com/highlight/detail?id=2544825579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544825579?lang=zh_cn&edition=full","pubTime":"2025-06-17 08:54","pubTimestamp":1750121655,"startTime":"0","endTime":"0","summary":"证券之星消息，万邦医药(301520)06月16日在投资者关系平台上答复投资者关心的问题。投资者提问：截至到2025年6月10日贵公司的股东人数是多少？万邦医药回复：尊敬的投资者您好，截止2025年6月10日，公司的股东人数为12,206户，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061700005361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301520","BK0216"],"gpt_icon":0},{"id":"2542914373","title":"【CRO概念震荡走低 联化科技跌停】CRO概念震荡走低，联化科技跌停，万邦医药、河化股份、翰宇药业、睿智医药、昭衍新药等跟跌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542914373","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542914373?lang=zh_cn&edition=full","pubTime":"2025-06-11 11:09","pubTimestamp":1749611373,"startTime":"0","endTime":"0","summary":"CRO概念震荡走低，联化科技跌停，万邦医药、河化股份、翰宇药业、睿智医药、昭衍新药等跟跌。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/11110950996739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06127","BK0239","BK0004","BK1141","BK0071","BK0188","BK0070","BK0066","BK1576","BK0028","BK0118","300149","002250","301520","603127","000953","300199","BK0077","BK0010","BK0229","BK0216"],"gpt_icon":0},{"id":"2542388571","title":"万邦医药收盘上涨8.99%，滚动市盈率44.32倍，总市值30.00亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542388571","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542388571?lang=zh_cn&edition=full","pubTime":"2025-06-09 17:56","pubTimestamp":1749463001,"startTime":"0","endTime":"0","summary":"6月9日，万邦医药今日收盘45.0元，上涨8.99%，滚动市盈率PE达到44.32倍，创139天以来新低，总市值30.00亿元。从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均41.42倍，行业中值44.32倍，万邦医药排名第30位。股东方面，截至2025年3月31日，万邦医药股东户数9256户，较上次增加583户，户均持股市值35.28万元，户均持股数量2.76万股。安徽万邦医药科技股份有限公司的主营业务是为医药企业和其他医药研发机构提供专业化医药研发外包服务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/09175650951699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2535351057","title":"万邦医药：公司有为改善干眼症的麦角硫因洗眼液项目提供临床功效试验服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2535351057","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535351057?lang=zh_cn&edition=full","pubTime":"2025-05-16 16:06","pubTimestamp":1747382776,"startTime":"0","endTime":"0","summary":"证券之星消息，万邦医药(301520)05月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好，请问贵公司有没有研究护眼用药物麦角硫因？谢谢，忘回答万邦医药回复：尊敬的投资者您好，公司有为改善干眼症的麦角硫因洗眼液项目提供临床功效试验服务，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051600022589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2535358848","title":"【万邦医药：与仅三生物在麦角硫因方面有临床项目合作】万邦医药在互动平台表示，公司与仅三生物在麦角硫因方面有临床项目合作，公司为仅三生物研发的产品提供功效性验证临床服务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535358848","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535358848?lang=zh_cn&edition=full","pubTime":"2025-05-16 14:19","pubTimestamp":1747376368,"startTime":"0","endTime":"0","summary":"万邦医药在互动平台表示，公司与仅三生物在麦角硫因方面有临床项目合作，公司为仅三生物研发的产品提供功效性验证临床服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/16141950441806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2535633322","title":"万邦医药：公司研究了麦角硫因的潜在多种功效","url":"https://stock-news.laohu8.com/highlight/detail?id=2535633322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535633322?lang=zh_cn&edition=full","pubTime":"2025-05-16 11:33","pubTimestamp":1747366408,"startTime":"0","endTime":"0","summary":"证券之星消息，万邦医药(301520)05月16日在投资者关系平台上答复投资者关心的问题。投资者提问：介绍一下贵公司在麦角硫因方面的研究万邦医药回复：尊敬的投资者您好，公司研究了麦角硫因的潜在多种功效，通过人体试食试验验证功效并且探索在人体内的作用机制，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051600013450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301520","BK0216"],"gpt_icon":0},{"id":"2535332283","title":"万邦医药：公司与仅三生物在麦角硫因方面有临床项目合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2535332283","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535332283?lang=zh_cn&edition=full","pubTime":"2025-05-16 11:33","pubTimestamp":1747366408,"startTime":"0","endTime":"0","summary":"证券之星消息，万邦医药(301520)05月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司是否和仅三生物在麦角硫因方面有合作？请具体介绍万邦医药回复：尊敬的投资者您好，公司与仅三生物在麦角硫因方面有临床项目合作，我公司为仅三生物研发的产品提供功效性验证临床服务，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051600013449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301520","BK0216"],"gpt_icon":0},{"id":"2530157475","title":"万邦医药收盘下跌2.27%，滚动市盈率35.14倍，总市值23.79亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530157475","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530157475?lang=zh_cn&edition=full","pubTime":"2025-04-28 18:26","pubTimestamp":1745836012,"startTime":"0","endTime":"0","summary":"4月28日，万邦医药今日收盘35.68元，下跌2.27%，滚动市盈率PE达到35.14倍，总市值23.79亿元。从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均40.74倍，行业中值42.36倍，万邦医药排名第27位。资金流向方面，4月28日，万邦医药主力资金净流出265.02万元，近5日总体呈流出状态，5日共流出1697.32万元。安徽万邦医药科技股份有限公司的主营业务是为医药企业和其他医药研发机构提供专业化医药研发外包服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/28182649959933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2529180356","title":"万邦医药(301520.SZ)发布2024年度业绩，归母净利润8553.07万元，下降20.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529180356","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529180356?lang=zh_cn&edition=full","pubTime":"2025-04-21 19:52","pubTimestamp":1745236320,"startTime":"0","endTime":"0","summary":"万邦医药(301520.SZ)发布2024年年度报告，该公司营业收入为3.79亿元，同比增长10.91%。归属于上市公司股东的净利润为8553.07万元，同比减少20.87%。归属于上市公司股东的扣除非经常性损益的净利润为5578.78万元，同比减少42.90%。基本每股收益为1.28元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-21/doc-inetxsmq8551293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301520"],"gpt_icon":0},{"id":"2529870456","title":"万邦医药(301520.SZ)发布一季度业绩，归母净利润1184.93万元，下降60.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529870456","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529870456?lang=zh_cn&edition=full","pubTime":"2025-04-21 19:49","pubTimestamp":1745236175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万邦医药(301520.SZ)发布2025年第一季度报告，该公司营业收入为7105.22万元，同比减少21.20%。归属于上市公司股东的净利润为1184.93万元，同比减少60.09%。归属于上市公司股东的扣除非经常性损益的净利润为535.89万元，同比减少76.44%。基本每股收益为0.18元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301520"],"gpt_icon":0},{"id":"2514933344","title":"万邦医药最新公告：证券事务代表杨婷因个人原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2514933344","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514933344?lang=zh_cn&edition=full","pubTime":"2025-02-28 18:30","pubTimestamp":1740738611,"startTime":"0","endTime":"0","summary":"万邦医药(301520.SZ)公告称，公司董事会近日收到证券事务代表杨婷的书面辞职报告，杨婷因个人原因申请辞去公司证券事务代表职务。杨婷的辞职不会影响公司相关工作的正常开展，公司将尽快聘任新的证券事务代表。杨婷在任职期间恪尽职守、勤勉尽责，公司对其表示感谢。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022800036185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301520","161027","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1755773578743,"stockEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":-0.0177},{"period":"3month","weight":0.1891},{"period":"6month","weight":0.0525},{"period":"1year","weight":0.2242},{"period":"ytd","weight":0.2083}],"compareEarnings":[{"period":"1week","weight":0.0225},{"period":"1month","weight":0.058},{"period":"3month","weight":0.1142},{"period":"6month","weight":0.1146},{"period":"1year","weight":0.3138},{"period":"ytd","weight":0.1237}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"安徽万邦医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"9277人(较上一季度减少6.77%)","perCapita":"2417股","listingDate":"2023-09-25","address":"安徽省合肥市蜀山区高新区火龙地路299号","registeredCapital":"6666万元","survey":" 安徽万邦医药科技股份有限公司的主营业务是为医药企业和其他医药研发机构提供专业化医药研发外包服务。公司的主要产品是临床试验现场管理（SMO）、生物样本分析（BA）、数据管理与统计分析（DM/ST）、处方工艺研究、质量研究、稳定性研究。","listedPrice":67.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.9","shortVersion":"4.34.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万邦医药(301520)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万邦医药(301520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万邦医药,301520,万邦医药股票,万邦医药股票老虎,万邦医药股票老虎国际,万邦医药行情,万邦医药股票行情,万邦医药股价,万邦医药股市,万邦医药股票价格,万邦医药股票交易,万邦医药股票购买,万邦医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万邦医药(301520)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万邦医药(301520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}